Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Cosentyx available in U.S. for treatment of ankylosing spondylitis and psoriatic arthritis

Jan. 21, 2016

Lilly files NDA for baricitinib for the oral treatment of rheumatoid arthritis

Jan. 20, 2016

FDA approves Cosentyx for ankylosing spondylitis and psoriatic arthritis

Jan. 18, 2016

EMA approves Samsung Bioepis's biosimilar etanercept Benepali

Jan. 18, 2016

AbbVie begins phase III program evaluating ABT-494 for rheumatoid arthritis

Jan. 11, 2016

FDA accepts for review sarilumab BLA for rheumatoid arthritis

Jan. 8, 2016

Mice homozygous for LGMD2I-causing FKRP mutation show progressive myopathy

Jan. 8, 2016

Novel preclinical model for cancer cachexia

Dec. 30, 2015

PI3Kdelta inhibitors revealed in Merck & Co. patent

Dec. 29, 2015

Biosimilar adalimumab M-923 met primary endpoint in pharmacokinetic study

Dec. 24, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...